康希諾生物(06185.HK): 吸入用新冠疫苗不會帶來公司業績的大幅增長
格隆匯11月3日丨康希諾生物(06185.HK)發佈公吿,公司股票於2022年10月31日、11月1日及11月2日連續3個交易日內日收盤價格漲幅偏離值累計超過30%,根據《上海證券交易所交易規則》、《上海證券交易所科創板股票交易特別規定》、《上海證券交易所科創板股票異常交易實時監控細則(試行)》的有關規定,屬於股票交易異常波動情形。
基於當前的免疫策略及國內加強針接種率較高的情況,公司預期吸入用重組新型冠狀病毒疫苗(5型腺病毒載體)(以下簡稱“吸入用新冠疫苗”)不會帶來公司業績的大幅增長。
2022年1-9月,公司對存貨計提資產減值準備合計52,617.59萬元。因新冠疫苗需求量較去年同期大幅下降、產品價格調整以及對存在減值跡象的存貨計提跌價準備,公司2022年1-9月營業收入、淨利潤較去年同期都出現較大幅度的下降,合計計提的資產減值準備預計將減少公司2022年度合併報表利潤總額53,244.54萬元,減少淨利潤45,792.46萬元,減少歸屬於上市公司股東的淨利潤44,003.21萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.